Fundraising FoxAnimol
Boston, US · Founded 2018 · 3 known investors
Find your way into Animol
Sign up to see every warm intro you have to Animol
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Animol team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Animol is a biopharmaceutical company developing a proprietary pipeline of novel veterinary small-molecule drugs for both companion and farm animals, targeting areas from anti-parasitics to chronic diseases. It uses a technology platform to discover active pharmaceutical ingredients designed for veterinary patients.
Founders & leadership
Animol was founded in 2018 by Andrew Calabrese and Andrew Calabrese, Ph.D..
Board
Investors · 3
How we know: the company's own site · board seat on SEC Form D · Not right? Tell us
How we know: the company's own site · a partner's Signal profile · the VCSheet dataset · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$36M disclosed across 2 rounds · 2022–2024
▶$4MraisedDec 2024 · 1 investors · OtherRule 506(b)
- Marijn DekkersDirector
- Michelle HavenDirector
- Philip AustinExecutive Officer, Director
- Offering amount
- $4M
- Amount sold
- $4M
- First sale
- Nov 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$32MraisedAug 2022 · 3 investors · OtherRule 506(b)
- Michelle HavenDirector
- Philip AustinExecutive Officer, Director
- Andrew PlantExecutive Officer, Director
- Marijn DekkersDirector
- Offering amount
- $32M
- Amount sold
- $32M
- First sale
- Jul 2022
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 2
Companies working in the same space as Animol.
Frequently asked questions
- What does Animol do?
- Animol is a biopharmaceutical company developing a proprietary pipeline of novel veterinary small-molecule drugs for both companion and farm animals, targeting areas from anti-parasitics to chronic diseases. It uses a technology platform to discover active pharmaceutical ingredients designed for veterinary patients.
- Who founded Animol?
- Animol was founded by Andrew Calabrese, Andrew Calabrese, Ph.D. in 2018.
- Who are Animol's investors?
- Animol's investors include Novalis LifeSciences, Anterra Capital, DYDX Capital.
- How much funding has Animol raised?
- Animol has disclosed $36M raised across 2 rounds.
- Where is Animol headquartered?
- Animol is headquartered in Boston, US.